%0 Journal Article
%T First oncolytic virus approved for melanoma immunotherapy
%A Guido Kroemer
%A Jonathan Pol
%A Lorenzo Galluzzi
%J Archive of "Oncoimmunology".
%D 2016
%R 10.1080/2162402X.2015.1115641
%X On 2015, October 27th, the US Food and Drug Administration (FDA) has officially approved talimogene laherparepvec (T-VEC, also known as OncoVEXGM-CSF) for use in melanoma patients with injectable but non-resectable lesions in the skin and lymph nodes. T-VEC (which is commercialized by Amgen, Inc. under the name of Imlygic£¿) becomes therefore the first oncolytic virus approved for cancer therapy in the US
%K Granulocyte macrophage colony-stimulating factor
%K Imlygic£¿
%K OncoVEXGM-CSF
%K OPTiM
%K talimogene laherparepvec
%K T-vec
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4760283/